首頁 > 市場調查報告書 > 製藥

骨疾病

骨質疏鬆症藥物市場規模、佔有率和成長分析（按藥物類別、給藥途徑、適應症和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1900301

骨質疏鬆症藥物市場規模、佔有率和成長分析（按藥物類別、給藥途徑、適應症和地區分類）－2026-2033年產業預測

Osteoporosis Drugs Market Size, Share, and Growth Analysis, By Drug Class (Rank Ligand Inhibitors, Bisphosphonates), By Route of Administration (Oral, Injectable), By Application, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，骨質疏鬆症藥物市場規模將達到 75.9 億美元，到 2025 年將達到 78.5 億美元，到 2033 年將達到 102.5 億美元，在預測期（2026-2033 年）內，複合年成長率為 3.4%。

骨質疏鬆症治療市場正經歷顯著的進步，這主要得益於創新醫療技術的推動，特別是新型藥物輸送系統和先進的骨質密度檢測設備。這些發展拓寬了治療選擇，改善了患者的治療效果，並提振了骨質疏鬆症治療市場的未來前景。這些藥物旨在預防、治療和控制骨質疏鬆症——一種以骨量減少和骨骼脆弱性增加為特徵的疾病——它們能夠增強骨骼強度，減緩骨質流失，並降低骨折風險。市場成長的驅動力來自持續的藥物研發活動、對綜合健康解決方案日益成長的需求以及對骨折預防的日益重視。此外，新興的生物療法，例如靶向單株抗體，有望為對傳統療法無效的患者提供有效的替代方案，而機器學習和人工智慧等創新技術正在簡化研發流程。

骨質疏鬆症藥物市場促進因素

全球骨質疏鬆症治療市場的主要促進因素之一是人口老化和預期壽命延長導致骨質疏鬆症及骨骼相關疾病的盛行率不斷上升。人口結構變化使更多人面臨骨骼密度降低等疾病的風險，進而導致骨折及相關併發症的發生率增加。這一日益嚴重的健康問題推動了對有效骨質疏鬆症治療藥物的需求成長，並促進了藥物研發。此外，醫護人員和患者對骨質疏鬆症管理和預防措施的認知不斷提高，也進一步推動了市場發展，為創新治療方案和策略性市場成長創造了機會。

骨質疏鬆症藥物市場的限制

全球骨質疏鬆症治療市場的主要限制因素之一是創新治療方法的高成本，這可能會限制患者的用藥途徑。隨著人口老化和骨質疏鬆症盛行率的上升，對有效治療方法的需求日益成長，但許多患者可能無法負擔這些先進藥物的費用，或沒有醫療保險。此外，治療方案的複雜性和潛在的副作用可能會降低患者的依從性，從而阻礙市場成長。另外，人們越來越重視成本效益高的醫療保健解決方案，這可能會導致人們更傾向於選擇學名藥，這可能會影響市場動態。

骨質疏鬆症藥物市場趨勢

骨質疏鬆症治療市場正呈現出顯著且不斷成長的趨勢，即採用注射療法，特別是成骨劑和成骨抑制劑，這些療法以其高效性和持久作用而著稱。這些注射療法特別適用於重度骨質疏鬆症患者，有效滿足了重要的醫療需求，並推動了市場需求。隨著醫療服務提供者越來越重視個人化治療方案和改善患者預後，向這些先進治療方法的轉變凸顯了骨質疏鬆症治療領域向創新和永續解決方案發展的更廣泛趨勢。這一趨勢體現了改善骨質疏鬆症患者生活品質的整體性方法。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Amgen Inc.（US）
Eli Lilly and Company（US）
Merck & Co., Inc.（US）
Novartis International AG（Switzerland）
Pfizer Inc.（US）
GlaxoSmithKline plc（UK）
Radius Health, Inc.（US）
UCB SA（Belgium）
Teva Pharmaceutical Industries Ltd.（Israel）
Roche Holding AG（Switzerland）
Bristol-Myers Squibb Company（US）
Sanofi SA（France）
AbbVie Inc.（US）
AstraZeneca PLC（UK）
Hologic, Inc.（US）
Lundbeck A/S（Denmark）
Eisai Co., Ltd.（Japan）
Ferring Pharmaceuticals（Switzerland）
Sandoz International GmbH（Switzerland）
Servier Laboratories（France）
Bayer AG（Germany）
Grunenthal GmbH（Germany）

簡介目錄

Product Code: SQMIG35I2282

Osteoporosis Drugs Market size was valued at USD 7.59 Billion in 2024 and is poised to grow from USD 7.85 Billion in 2025 to USD 10.25 Billion by 2033, growing at a CAGR of 3.4% during the forecast period (2026-2033).

The osteoporosis drug market is witnessing significant advancements fueled by innovative medical technologies, including novel medication delivery systems and enhanced bone density measurement devices. These developments yield a broader array of treatment options, yielding improved patient outcomes and enhancing the future market prospects for osteoporosis therapies. Designed to prevent, treat, and manage osteoporosis-which involves decreased bone mass and increased fragility-these medications bolster bone strength, slow down loss, and diminish fracture risk. The market growth is driven by ongoing drug discovery, heightened demand for integrated health solutions, and a focus on fracture prevention. Additionally, emergent biologic therapies, such as targeted monoclonal antibodies, promise effective alternatives for patients with non-responsiveness to traditional treatments, while innovations like machine learning and artificial intelligence are streamlining research and development efforts.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoporosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoporosis Drugs Market Segments Analysis

Global Osteoporosis Drugs Market is segmented by Drug Class, Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Branded, and Generic. Based on Type, the market is segmented into Bisphosphonates, Parathyroid Hormone, Calcitonin, Selective Estrogen Inhibitor Modulator, Rank Ligand Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Osteoporosis Drugs Market

One key market driver for the Global Osteoporosis Drugs Market is the increasing prevalence of osteoporosis and bone-related disorders, largely attributed to an aging population and rising life expectancy. As the demographic landscape shifts, more individuals are at risk for conditions characterized by decreased bone density, leading to a higher incidence of fractures and related complications. This growing health concern prompts greater demand for effective osteoporosis treatments, driving pharmaceutical research and development. Additionally, heightened awareness about osteoporosis management and preventive measures among healthcare professionals and patients further fuels the market, creating opportunities for innovative therapeutic solutions and strategic market growth.

Restraints in the Osteoporosis Drugs Market

One key market restraint for the global osteoporosis drugs market is the high cost of innovative therapies, which can limit accessibility for patients. As the population ages and the prevalence of osteoporosis increases, the demand for effective treatments rises; however, many patients may be unable to afford these advanced medications or lack insurance coverage. Additionally, the complexity of treatment regimens and potential side effects can discourage adherence, further hindering market growth. Furthermore, the increasing emphasis on cost-effective healthcare solutions may lead to a preference for generic medications over pricier branded options, impacting the overall market dynamics.

Market Trends of the Osteoporosis Drugs Market

The osteoporosis drugs market is witnessing a notable trend towards the increasing adoption of injectable therapies, particularly Rank Ligand Inhibitors and anabolic agents, which are recognized for their significant efficacy and extended duration of action. These injectable treatments are particularly well-suited for patients with severe osteoporosis, effectively addressing critical health needs and driving demand within the market. As healthcare providers emphasize tailored treatment options and improved patient outcomes, the shift towards these advanced therapeutic modalities underscores a broader movement towards innovative, long-lasting solutions in osteoporosis care. This trend reflects an overall commitment to enhancing quality of life for individuals affected by this chronic condition.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Osteoporosis Drugs Market by Drug Class

Market Overview
Branded
Generic

Osteoporosis Drugs Market by Type

Market Overview
Bisphosphonates
Parathyroid Hormone
Calcitonin
Selective Estrogen Inhibitor Modulator
Rank Ligand Inhibitor
Others

Osteoporosis Drugs Market by Distribution Channel

Market Overview
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy

Osteoporosis Drugs Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radius Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Servier Laboratories (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grunenthal GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments